0000000001249603

AUTHOR

M. Schroeder

showing 3 related works from this author

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and…

2019

Abstract Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition of docetaxel to PFC improved efficacy in R/M SCCHN. Methods A total of 180 patients with R/M SCCHN (1:1) were assigned to receive either cisplatin (40 mg/m2), docetaxel (40 mg/m2) and 5-FU (2000 mg/m2) at days 1 and 8 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (DPFC) or standard cisplatin (100 mg/m2) at day 1, 5-FU (1000 mg/m2) at days 1–4 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (PFC). Chemotherapy was…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinCetuximabDocetaxelDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAgedCisplatinChemotherapyCetuximabbusiness.industrySquamous Cell Carcinoma of Head and NeckHead and neck cancerHazard ratioMiddle AgedInterim analysismedicine.disease030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisFemaleFluorouracilCisplatinbusinessmedicine.drug
researchProduct

A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.

2002

Ftorafur is an orally available prodrug of 5-fluorouracil (5-FU). Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone. Paclitaxel has a broad spectrum of activity against solid tumors and synergic effects with UFT have been demonstrated in vitro. A phase I study was performed to determine the maximum tolerated dose of the combination of UFT and paclitaxel in patients with advanced solid tumors.UFT and folinic acid were applied at 300 mg/m2/day and 90 mg/day, respectively, on days 1-28, repeated on day 36. Paclitaxel was applied on days 1, 8, 15 and 22 of each cycle. The starting dose of paclitaxel was 50 mg/m…

AdultMalemedicine.medical_specialtyMaximum Tolerated DosePaclitaxelmedicine.medical_treatmentLeucovorinAdministration OralPharmacologyTegafurGastroenterologyDrug Administration Schedulechemistry.chemical_compoundFolinic acidLeukocytopeniaOral administrationInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedTegafurChemotherapyDose-Response Relationship Drugbusiness.industryHematologyMiddle AgedSurvival AnalysisTreatment OutcomeOncologyPaclitaxelchemistryFluorouracilToxicityFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Search for neutral MSSM Higgs bosons at LEP

2006

The four LEP collaborations, ALEPH, DELPHI, L3 and OPAL, have searched for the neutral Higgs bosons which are predicted by the Minimal Supersymmetric Standard Model (MSSM). The data of the four collaborations are statistically combined and examined for their consistency with the background hypothesis and with a possible Higgs boson signal. The combined LEP data show no significant excess of events which would indicate the production of Higgs bosons. The search results are used to set upper bounds on the cross-sections of various Higgs-like event topologies. The results are interpreted within the MSSM in a number of "benchmark" models, including CP-conserving and CP-violating scenarios. Thes…

AlephPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; ALEPH; DELPHI; L3; OPALPhysics and Astronomy (miscellaneous)Parameter space01 natural sciencesOPAL DETECTORHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Event (probability theory)BosonPhysicsEXPLICIT CP VIOLATIONROOT-S=189 GEVOPALFLAVOR INDEPENDENT SEARCHParticle physics - ExperimentPhysicsSettore FIS/01 - Fisica SperimentaleHiggs particle. search forSUPERGAUGE TRANSFORMATIONSALEPHLARGE ELECTRON POSITRON COLLIDERALEPH DELPHI L3 OPALSUPERSYMMETRIC STANDARD MODELROOT-SL3Higgs bosonPARTICLE PHYSICSParticle physicselectron positron. colliding beamselectron positron. annihilationFOS: Physical sciencessupersymmetric standard model;; explicit cp violation;; electric-dipole moment;; e(+)e(-) collisions;; root-s=189 gev;; opal detector;; root-s;; z(0) decays;; supergauge transformations;; radiative-correctionsHiggs particle. electroproductionddc:500.2-SUPERSYMMETRIC STANDARD MODEL; EXPLICIT CP VIOLATION; FLAVOR INDEPENDENT SEARCH; ELECTRIC-DIPOLE MOMENT; E(+)E(-) COLLISIONS; ROOT-S; ROOT-S=189 GEV; OPAL DETECTOR; Z(0) DECAYS; SUPERGAUGE TRANSFORMATIONSHiggs particleLEP colliderNext-to-Minimal Supersymmetric Standard ModelELECTRIC-DIPOLE MOMENTE(+)E(-) COLLISIONSConsistency (statistics)0103 physical sciencesddc:530High Energy Physics010306 general physicsEngineering (miscellaneous)DELPHIelectron positron010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyHiggs BosonLEPHIGGSHiggs boson standard modelZ(0) DECAYSExperimental High Energy PhysicsHigh Energy Physics::ExperimentHiggs Boson; LEP colliderMSSMMinimal Supersymmetric Standard ModelHiggs
researchProduct